ENXTPA:VIRPPharmaceuticals
Virbac (ENXTPA:VIRP) Margin Holds Near 10% Keeping Growth Narrative Intact
Virbac (ENXTPA:VIRP) has put fresh numbers on the table for FY 2025, reporting second half revenue of €726.4 million and net income of €68.5 million, while the trailing twelve month figures stand at €1.46 billion of revenue and €150.9 million of net income. The company’s revenue has moved from €694.4 million and net income of €50.6 million in 2024 H2 to €726.4 million and €68.5 million in 2025 H2. This comes alongside trailing EPS of €15.88 and sets up a story where investors will be weighing...